However, clinical data disproves this contention: Gulley et al. (2005) administered a poxviral vaccine encoding prostate-specific antigen (PSA) to 17 prostate cancer patients undergoing radiotherapy with total external beam dose ≥70 Gy given in 1.8 to 2.0 Gy per fraction. This evidence concerns the gene KLK3 and prostate cancer.